BeOne Medicines Ltd. — Director's Dealing 2024

Jun 7, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2024-06-05

Reporting Person: OYLER JOHN (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-05	Ordinary Shares	A	490464	—	Acquired	1812018	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-05	Share Option (Right to Buy)	$12.23	A	923975	Acquired	2034-06-04	Ordinary Shares (923975)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	481533	Indirect
Ordinary Shares	7727927	Indirect
Ordinary Shares	28334115	Indirect
Ordinary Shares	9545000	Indirect
Ordinary Shares	102188	Indirect

Footnotes

F1: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F2: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F4: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F5: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.

F6: These securities are held by The John Oyler Legacy Trust, of which the Reporting Person's father is a trustee, for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

F7: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F8: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events.